The US FDA's Center for Biologics Evaluation and Research (CBER) has published final guidance consolidating frequently asked questions on the development of cellular and gene therapy (CGT) products, spanning regulatory interactions, manufacturing controls, nonclinical studies, and clinical trial design. The August 2026 guidance, prepared by CBER's Office of Therapeutic Products (OTP) under docket FDA-2024-D-4311, finalizes a draft issued in September 2024 and fulfills an FDA commitment under PDUFA VII to improve the efficiency of CGT development.
What it covers
The guidance consolidates OTP's responses to recurring questions raised by CGT developers through regulatory interactions, public presentations, and the office's virtual town hall series. Rather than establishing a new regulatory framework, it provides a single reference for how FDA currently applies existing regulatory principles across much of the CGT development lifecycle.
On regulatory interactions, the guidance clarifies the appropriate use of INTERACT, pre-IND, Type D, and pre-BLA meetings and addresses submission and review procedures, including electronic common technical document requirements and rolling review of qualifying biologics license applications (BLAs).
The chemistry, manufacturing, and controls (CMC) sections distinguish product characterization from release testing and address critical quality attribute identification, phase-appropriate analytical methods, process validation, and manufacturing readiness at BLA submission. The guidance emphasizes that analytical methods used during early clinical development should be fit for their intended purpose, with the level of validation and process characterization increasing as a program approaches commercialization.
For nonclinical development, FDA addresses animal species selection, use of analogous products when the clinical candidate cannot be appropriately evaluated in standard models, tumorigenicity assessment, proof-of-concept studies, biodistribution, and translation of dose levels from animals to humans. The agency also indicates that alternative approaches, including new approach methodologies and non-animal methods, may be considered when scientifically justified.
Clinical sections address selection of control groups, substantial evidence of effectiveness, surrogate endpoints, accelerated versus traditional approval pathways, staggered enrollment, and long-term follow-up. For gene therapies with characteristics that create a risk of delayed adverse events, FDA may recommend extended patient monitoring, potentially lasting as long as 15 years depending on the product and its persistence or integration characteristics.
Why it matters
The principal value of the final guidance is consolidation rather than the creation of new regulatory standards. It gives CGT developers a clearer operational map of how OTP applies existing FDA requirements and flexibilities, potentially reducing uncertainty over when to approach the agency and what level of evidence is expected at different stages of development.
The guidance is particularly relevant to rare disease programs. FDA reiterates that the conventional phase assigned to a clinical trial does not determine whether it can provide substantial evidence of effectiveness. In appropriate circumstances, a well-designed early-stage study incorporating efficacy endpoints could contribute pivotal evidence, an important consideration for ultra-rare diseases where conventional large development programs may not be feasible. FDA also reiterates that a single adequate and well-controlled investigation supported by confirmatory evidence can satisfy the statutory substantial evidence standard in appropriate circumstances.